Cyllene Therapeutics
8 known investors
Find your way into Cyllene Therapeutics
Cyllene Therapeutics develops a gene therapy platform based on non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors to deliver DNA medicines for patients with severe localized chronic diseases. Its initial focus is peripheral nervous system disorders, with its most advanced program targeting Type C neurons to treat underserved bladder disorders.
Investors · 8
M VenturesLos Angeles · $10.8M
SCI VenturesLondon
Andera Partnersreported · 3 sourcesParis
Bpifrancereported · 2 sourcesParis, Ile-De-France · $270K
Also in the syndicate · 4
GordonMD Global InvestmentsleadGordonMD Global Investments® LPleadLamond Ventures LLCMerck KGaA's venture armlead
Funding
SEC filings, press & company announcements$37M disclosed across 1 round · 2026
- $37MSeries CJul 2026 · 5 sources
GordonMD Global Investments (lead), GordonMD Global Investments® LP (lead), M Ventures (lead), Merck KGaA's venture arm (lead), Andera Partners SAS, Bpifrance Investissement, Lamond Ventures LLC
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Cyllene Therapeutics do?
- Cyllene Therapeutics develops a gene therapy platform based on non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors to deliver DNA medicines for patients with severe localized chronic diseases. Its initial focus is peripheral nervous system disorders, with its most advanced program targeting Type C neurons to treat underserved bladder disorders.
- Who are Cyllene Therapeutics's investors?
- Cyllene Therapeutics's investors include M Ventures, SCI Ventures, Andera Partners, Bpifrance.
- How much funding has Cyllene Therapeutics raised?
- Cyllene Therapeutics has disclosed $37M raised across 1 round.